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Abstract
Background: Interferon-induced cellular proteins play important roles in the host response against viral infection.
The Mx family of dynamin-like GTPases, which include MxA and MxB, target a wide variety of viruses. Despite
considerable evidence demonstrating the breadth of antiviral activity of MxA, human MxB was only recently
discovered to specifically inhibit lentiviruses. Here we assess both host and viral determinants that underlie MxB
restriction of HIV-1 infection.
Results: Heterologous expression of MxB in human osteosarcoma cells potently inhibited HIV-1 infection (~12-fold),
yet had little to no effect on divergent retroviruses. The anti-HIV effect manifested as a partial block in the formation
of 2-long terminal repeat circle DNA and hence nuclear import, and we accordingly found evidence for an additional
post-nuclear entry block. A large number of previously characterized capsid mutations, as well as mutations that
abrogated integrase activity, counteracted MxB restriction. MxB expression suppressed integration into gene-enriched
regions of chromosomes, similar to affects observed previously when cells were depleted for nuclear transport factors
such as transportin 3. MxB activity did not require predicted GTPase active site residues or a series of unstructured loops
within the stalk domain that confer functional oligomerization to related dynamin family proteins. In contrast, we
observed an N-terminal stretch of residues in MxB to harbor key determinants. Protein localization conferred by a
nuclear localization signal (NLS) within the N-terminal 25 residues, which was critical, was fully rescuable by a
heterologous NLS. Consistent with this observation, a heterologous nuclear export sequence (NES) abolished
full-length MxB activity. We additionally mapped sub-regions within amino acids 26–90 that contribute to MxB
activity, finding sequences present within residues 27–50 particularly important.
Conclusions: MxB inhibits HIV-1 by interfering with minimally two steps of infection, nuclear entry and post-nuclear
trafficking and/or integration, without destabilizing the inherent catalytic activity of viral preintegration complexes.
Putative MxB GTPase active site residues and stalk domain Loop 4 – both previously shown to be necessary for
MxA function – were dispensable for MxB antiviral activity. Instead, we highlight subcellular localization and a
yet-determined function(s) present in the unique MxB N-terminal region to be required for HIV-1 restriction.
Keywords: Innate immunity, MxB, Mx2, HIV-1, Restriction factor
Background
Host organisms have developed a wide array of innate
immunity proteins to prevent or mitigate viral infection.
Expression of these proteins is often induced by inter-
feron signaling, as their potent activities can come at
the cost of host cell or organism viability. The study of
retroviruses in particular has uncovered many examples
of innate antiviral proteins, including apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like (APO-
BEC) 3G [1], tripartite motif (TRIM) 5α [2] and TrimCyp
[3], SAM domain and HD domain-containing protein
(SAMHD) 1 [4,5], and bone marrow stromal cell antigen
(BST) 2/Tetherin [6,7]. Recently, Myxovirus resistance
protein 2 (MxB) was discovered to exhibit potent antiviral
activity against HIV-1 infection [8-11].
In humans, MxB is one of two members of a family of
dynamin-like large GTPases. Mx family proteins are found
in almost all vertebrates, demonstrating their evolutionary
importance for host organisms [12]. The X-ray crystal
structure of human MxA showed that these proteins can
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lar GTPase domain, a largely C-terminal alpha helical stalk
domain, and a series of alpha helices found in sequences
adjacent to these domains which fold in the protein ter-
tiary structure to form the bundle signaling element
(BSE) [13]. Mx proteins also possess relatively unstruc-
tured N-terminal regions of varying length. These proteins
readily multimerize into higher-order structures, with
MxA known to form large ring-like assemblies [14,15].
Human MxA inhibits infection by a large number of
negative-stranded RNA viruses, though it also counteracts
other viral families [12]. The ability of MxA to inhibit a
diverse set of viruses while specifically targeting different
proteins across these families is atypical amongst innate
immune proteins [16], suggesting an antiviral mechanism
distinct from those of previously discovered restriction
factors. Despite the breadth of known antiviral activities of
MxA, little is known about the antiviral potential of MxB.
Until recently, MxB was not thought to possess antiviral
activity, which suggested that its purpose was solely to
function during cellular nucleo-cytoplasmic transport
[17]. In contrast to MxA, which is cytoplasmic, MxB
localizes to the nuclear rim [18], which may play into
its distinct pattern of antiviral activity.
A large-scale screen assessing the activities of interferon
stimulated gene products against a panel of viruses first
uncovered an antiviral activity of human MxB against
HIV-1 [8]. More recently, a series of papers found MxB to
be a key component of the interferon-mediated response
against the early steps of HIV-1 infection [9-11]. The
reverse transcription complex wherein HIV-1 RNA is
reverse transcribed into double stranded linear DNA
carries a fraction of the virion capsid (CA) protein [19,20],
and CA mutations can accordingly confer resistance to
restriction by MxB [9-11]. The viral integrase (IN) protein
processes the long terminal repeat (LTR) ends of the viral
DNA to yield the integration-competent preintegration
complex (PIC), which subsequently transports the viral
DNA into the nucleus for IN-mediated integration [21].
Although the recent studies agreed that MxB expression
potently inhibited the early phase of HIV-1 replication
including integration, they differed in terms of where in
the lifecycle infection was blocked. For example, the mea-
sured effect on 2-LTR-containing DNA circles, which is
utilized as a marker for PIC nuclear import [22], ranged
from completely [9] or partially affected [11] to completely
unaffected [10]. Additionally, initial results from these
studies suggested MxB antiviral activity was independent
of its GTPase activity [9,11], yet dependent on the in-
clusion of an N-terminal sequence harboring a nuclear
localization signal (NLS) [11]. Here we clarify that MxB
restricts PIC nuclear import as well as HIV-1 integration.
Concordantly, our results confirm the critical nature of
the N-terminal region NLS, which can be functionally
exchanged by the heterologous basic-type NLS from
simian virus (SV) 40 large T antigen.
Results
Experimental system
We tested the activity of MxB by stably expressing a C-
terminally HA-tagged form in human osteosarcoma (HOS)
cells (Figure 1A). These cells, which were previously used
to dissect aspects of MxB antiviral activity [11], do not
express appreciable endogenous MxB protein, either in
the presence of absence of exogenously added interferon α
(Figure 1B). Immunofluorescent staining of wild type
(WT) MxB protein revealed that it localized to multiple
compartments within HOS cells: a substantial fraction of
MxB appeared as punctate signals within the cytoplasm,
though additional staining could be observed along the
nuclear rim (Figure 1C). Punctate cytoplasmic localization,
which has been reported previously [23], may reflect
the expression of N-terminal truncation products that
presumably lack the N-terminal NLS [23] (Figure 1A)
and/or protein aggregation. MxB potently restricted
HIV-1 under these conditions (P <0.001), reproducibly
inhibiting infection greater than 10-fold (Figure 1D).
MxB also restricted SIVmac (P ~0.002), though the
magnitude of this effect, ~2.6-fold, was significantly less
robust than its activity against HIV-1. MxB was not sig-
nificantly active against the more divergent lentiviruses
equine infectious anemia virus (EIAV) and feline immuno-
deficiency virus (FIV), or the gammaretrovirus Moloney
murine leukemia virus (MLV). Many of our subsequent
antiviral studies accordingly employed EIAV and FIV as
negative controls (see below).
Correlation of MxB restriction with CA-targeting factors
The CA protein, which is the HIV-1 factor that primarily
mediates PIC nuclear import [24], was previously found
to determine the sensitivity of HIV-1 to MxB [9-11]. We
assessed the sensitivities of a panel of 17 HIV-1 CA sin-
gle missense mutant viruses that were previously used to
investigate the mechanism of nucleoporin (NUP) 153
utility, and hence PIC nuclear import [25,26], to MxB
restriction. The inherent infectivities of the mutant viruses
spanned a relatively large range, from ~2% of the WT
virus for the G89V mutant to ≥100% of WT for N74D,
V86M, and T107N (Figure 2A). Consistent with the prior
reports, numerous mutants, most notably E45A, N57A,
N57S, K70R, G89V, P90A, and T107N, were signifi-
cantly less sensitive than the WT virus to MxB restriction
(P <0.02) (Figure 2B). In some cases, most notably for
T54A/N57A and N57D/P90A, the combination of muta-
tions yielded double mutant viruses that displayed less
sensitivity to MxB restriction as compared to the parental
mutants (Figure 2C and D).
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CA mutant viruses to similar profiles generated when
HIV-1 infection was perturbed through other means,
including restriction by TRIM5α or a truncated version
of cleavage and polyadenylation specific factor (CPSF) 6
(CPSF6358), or by cell growth arrest (Figure 2E and F)
[26]. We found that the pattern of HIV-1 CA mutant
virus resistance to MxB correlated strongly with those
resistant to rhesus TRIM5α (Spearman P <0.0001 for
the TFP allele; P = 0.0017 for the Q allele). There were
also significant correlations in CA mutant sensitivity to
CPSF6358-mediated restriction, NUP153 depletion, and
restriction by the artificial Trim-NUP153C fusion protein
that harbors the CA-interacting C-terminal region of
NUP153 (NUP153C) [26]. In contrast, there was only a
weak correlation with restriction by the Trim-CPSF6358
fusion protein, and a weak negative correlation with
sensitivity to growth arrest (Figure 2F and Additional
file 1: Figure S1).
IN activity as a secondary resistance determinant of MxB
restriction
The details of where MxB restricted HIV-1 infection dif-
fered among the initial set of reports. Although all three
papers found reverse transcription to be unaffected, Goujon
et al. [9] concluded that MxB restricted PIC nuclear import
whereas Liu et al. [10] reported that restriction occurred at
the downstream step of integration. We utilized a number
of assays, including quantitative (q) PCR readouts of reverse
transcription, nuclear import, and integration, to address
this issue (see below). To start, we assessed the sensitivity
of different IN mutant viruses to MxB restriction. Although
integration requires functional IN activity, IN active site
mutant viruses such as D64N/D116N can support transi-
ent, low level (~1-2% of WT) HIV-1 infection in the
absence of functional integration [25,27]. If PIC nuclear im-
port is inhibited without any downstream influence on
intranuclear trafficking or integration, D64N/D116N would
be as sensitive as the WT virus to MxB restriction. D64N/
D116N however was restricted to a significantly lower
extent than was WT HIV-1 (P ~2×10
−4)( F i g u r e3 A
and B). By contrast, the D167K IN mutant, which relies
on chromosomal DNA integration for its expression
[28], was as sensitive as the WT virus to MxB restriction.
Because D64N/D116N was significantly less infectious
than D167K (0.6% of the WT versus 18%; Figure 3A),
mutant viruses that carried alterations in genes other than
IN or CA, yet displayed similar levels of inherent infectiv-
ity, were used as controls. The H23C nucleocapsid (NC)
mutant, which is weakly infectious (~0.2% of WT) [29],
as well as the V148I reverse transcriptase (RT) mutant
[30] (~40% WT activity), were both as sensitive as the
WT virus to MxB restriction (Figure 3A and B). The
relative resistance of IN mutant D64N/D116N to MxB
restriction was moreover observed over a relatively wide
(250-fold) range of multiplicity of infection (Additional
file 2: Figure S2). Consistent with the existence of multiple
viral genetic determinants, resistance to MxB restriction
from IN inactivation was combinatorial with the partial
resistance conferred by the N74D CA mutation, yet
was epistatic with the full CA resistance mutant G89V
(Figure 3C and D).
MxB restricts nuclear import and integration
Levels of viral DNA intermediates at various times post-
infection in control versus MxB-expressing cells were
assessed by qPCR. PCR primers and probes were chosen
to monitor late reverse transcription (LRT) products that
form after the second template switch of viral DNA syn-
thesis, 2-LTR circles that form in the cell nucleus, and
HIV-1 integration [22,25,31,32]. The D64N/D116N mutant
was analyzed alongside the WT virus to gain insight into
the partial resistance conferred by IN inactivation. Under
these conditions, infection by the WT and D64N/D116N
viruses was restricted ~12 and 3.5-fold, respectively, by
MxB (Figure 4A).
Consistent with previous reports [9-11], WT and IN
mutant D64N/D116N viral reverse transcription was
largely unperturbed by MxB expression (Figure 4B, upper
panel). Different qPCR designs were utilized to assess
levels of 2-LTR circles. Ligation of linear viral DNA ends
that have not been processed by IN yields the novel circle
junction sequence [33]. Because the responsible non-
homologous DNA end joining (NHEJ) machinery resides
in the nucleus, 2-LTR circles are used as a surrogate
marker for PIC nuclear import [22,34]. HIV-1 however
undergoes significant autointegration during infection,
such that the processed LTR ends integrate into interior
regions of the viral genome [35,36]. Because the kinetics
of autointegration parallels that of viral DNA synthesis,
autointegration can presumably transpire in the cell cyto-
plasm before PIC nuclear import [36]. Autointegration
that occurs in the vicinity of the LTRs can score in 2-LTR
PCR assays and accordingly cloud PIC nuclear import
(See figure on previous page.)
Figure 1 MxB antiviral activities. (A) Western blot of HOS cells expressing MxB-HA. β-actin was monitored to control for sample loading. (B) Western
blot of untransduced or MxB-HA expressing HOS cell lysates extracted after treatment for 24 h with 1,000 U/ml of interferon α (IFN) as indicated.
(C) Immunofluorescence microscopy of HOS cells stably expressing MxB-HA or mock-transduced cells. Blue-tinted ovals demarcate cell nuclei due to
Hoescht 33342 staining of DNA. White horizontal bar, 10 μm. (D) Infection of MxB-HA expressing cells with various retroviral vectors plotted as percent
infection of mock-transduced cells. Results are a summary of 6 independent experiments with error bars denoting 95% confidence intervals.
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http://www.retrovirology.com/content/11/1/90Figure 2 HIV-1 CA and sensitivity to MxB restriction. (A) Infectivities of CA mutant viruses normalized to the WT by input level of exogenous
RT activity and expressed as percent of WT HIV-1 infection. (B) Sensitivity of the 17 CA single mutant viruses to MxB-HA, expressed as percent
infection versus mock-transduced cells. The single letter codes along the bottom of the graph represent the WT residue at that position. (C) Normalized
infectivities of 10 CA double mutant viruses relative to the WT. (D) Sensitivity of HIV-1 CA double missense mutant viruses (half black, half white filled
circles) as compared to the parental single mutant viruses. Q63A alone was not tested. (E) Scatterplot comparing the sensitivity of CA missense mutant
viruses to MxB-HA restriction with sensitivity to the rhesus TRIM5α TFP allele. (F) Pairwise comparison summary of MxB sensitivity with various
CA-related manipulations of host cells, with Spearman rank correlation and P values denoted; see Additional file 1: Figure S1 for the corresponding
scatterplots. Panel A-D results are averages of at least 6 independent experiments, with error bars denoting 95% confidence intervals.
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PCR assay conditions to take advantage of the unique
circle junction sequence that forms through NHEJ in
the cell nucleus. In one design, referred to here as Jxn2,
the 3′ end of the reverse PCR primer harbors the
nucleotides that are removed by IN prior to integration
whereas in the other Jxn1 design, the Taqman probe
spans the circle junction sequence [37].
Considering the ~12-fold block to HIV-1 infection, a
comparatively modest decrease (~3.9-fold at peak levels)
in the level of WT 2-LTR circles was observed in
MxB-expressing cells using qPCR conditions that do
not distinguish molecules that contain circle junction
sequences from those that may arise from autointegration
(Figure 4C, solid and dashed black lines). Jxn2 qPCR
yielded this same differential whereas the 2-LTR circle
Figure 3 Partial resistance of D64N/D116N IN active site mutant virus to MxB restriction. (A) Levels of NC mutant H23C, RT mutant V148I,
and IN mutant D167K and D64N/D116N infectivities, normalized to the WT based on input levels of exogenous RT activity, in control (dark grey)
versus MxB-expressing (light grey) cells. Results are plotted relative to the WT virus in control cells (set at 100%). (B) The re-plot of panel A results
highlights the infectivities of the indicated viruses in MxB-expressing cells relative to control cells. (C) RT-normalized levels of D64N/D116N IN mutant
infectivities with versus without additional CA mutations in control (dark grey) versus MxB-expressing (light grey) cells. The infectivity of the WTC A ,
D64N/D116N IN mutant virus in control cells was set to 100%. (D) Extent of MxB restriction of WT and CA mutant viruses that carry WT (dark grey) or
D64N/D116N (NN) mutant IN (white bars). Results are an average of 5 independent experiments, with error bars denoting 95% confidence intervals.
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design (Figure 4D and E, black lines). As expected, the
D64N/D116N mutant virus supported the formation of
significantly more 2-LTR circles than did the WT virus
[38-40] (Figure 4C-E left panels, red and black solid
lines). The IN mutant viral 2-LTR circle defect, measured
as ~4.4, 3.8, and 2.9-fold at peak levels using conventional,
Jxn2, and Jxn1 qPCR conditions, respectively, was roughly
similar to that of the WT virus (Figure 4C-E, red lines).
The level of WT HIV-1 integration in MxB-expressing
cells was ~7.4% of the level achieved in control cells,
which accounted for the 8.6% level of virus infection that
was assessed through bulk luciferase activity (Figure 4B,
lower panel and Figure 4A).
MxB expression alters the distribution of integrated
proviruses without affecting PIC integration activity
The results of the previous experiments indicated that
the defect in IN mutant D64N/D116N nuclear import,
which was ~3.7-fold by averaging the results of the
different 2-LTR qPCR assays, accounted for the 3.5-fold
infectivity defect of this virus. By contrast, the 2-LTR
circle defect of the WTvirus did not seem to fully account
for its infection or integration defect. Two additional
experiments were therefore performed to further probe
t h ee f f e c to fM x Be x p r e s s i o no nH I V - 1i n t e g r a t i o n .W e
first measured the ability of PIC-associated IN to support
the integration of endogenous viral DNA into heterol-
ogous target DNA in vitro, and subsequently assessed the
distribution of integrated proviruses across the cellular
genome. Cytoplasmic and nuclear PICs isolated from
MxB-expressing cells notably supported similar levels of
in vitro integration activities as those isolated from
matched control cells (Figure 5A).
The distribution of HIV-1 integration sites was assessed
using a ligation-mediated (LM)-PCR design modified to
sequence viral U5-cellular DNA junctions on the Illumina
platform (Figure 5B) [41,42]. In brief, cellular DNA
isolated from infected cells was digested with the 4-bp
cutter MseI and 6-bp cutter BglII; BglII was included to
suppress amplification of the MseI site that lies down-
stream from the internal copy of U5 in the upstream
LTR. The digested DNA was ligated to an asymmetric
linker containing a 5′-TA overhang, and the ligation
products were amplified by PCR using primers that
annealed to U5 and linker DNA. A key modification here
was the inclusion of heterologous sequences required for
sequencing, including Illumina P5 and P7 adapters, in the
PCR primers. Hence, only one round of PCR amplification
was required prior to sequencing. The resulting sequences
were parsed for U5 and linker DNA content, compared
to human genome build 19 (hg19), and annotated for
features such as genes, transcription start sites (TSSs),
CpG islands, and gene density. Products of HIV-1 auto-
integration, ambiguous cell DNA reads, and duplicated in-
tegration sites were omitted from the bioinformatics
analysis.
Control HOS cells yielded 476,305 unique HIV-1 inte-
gration sites whereas 50,065 were determined from MxB-
expressing cells (Table 1). As expected [41], HIV-1 greatly
favored integration into genes: 63.6% of control cell inte-
grations occurred within RefSeq genes whereas 36.1% was
the value expected based on a matched random control
(MRC) dataset of 476,280 computer-generated sites. In
the presence of MxB integration into genes fell off
somewhat, to 58.0% of the sites. This value was statistically
different from both the control HOS cell and MRC
numbers (Table 1).
HIV-1 integration frequencies surrounding TSSs and
CpG islands were initially determined for 5 kb (±2.5 kb)
windows. As previously observed [43], the level of
promoter proximal integration in control cells, 3.11%,
was similar to the MRC value of 3.22% (Table 1). MxB
expression modestly reduced the frequency obtained
from control cells to the value of 2.25%. Likely due to
our relatively large datasets, each of these differences
was nevertheless statistically significant. To gain further
insight into the effect of MxB restriction on the distribu-
tion of HIV-1 integration sites, provirus numbers within
expanded 60 kb windows (30 kb upstream to 30 kb
downstream of TSSs and CpG islands) were counted in
1.25 kb bins. The preference for HIV-1 to integrate into
gene bodies was evident throughout the window down-
stream from TSSs (Figure 6A and Additional file 3:
Figure S3A). By contrast, the virus sharply avoided
regions ~1.25 kb immediately upstream from TSSs.
MxB expression predominantly altered the control cell
integration pattern from ~12.5 kb upstream to 25 kb
(See figure on previous page.)
Figure 4 WT and D64N/D116N IN mutant DNA metabolism in control and MxB-expressing cells. (A) Levels of WT and D64N/D116N infectivities
in control (dark grey) and MxB-expressing (light grey) HOS cells normalized for input RT cpm; the level of WT HIV-1 infection in control cells was set to
100% (left panel). Right panel, re-plot to highlight le v e l so fW Ta n dD 6 4 N / D 1 1 6 NI Nm u t a n tr e s t r i c t i o nb yM x B .(B) Upper panel, WT and D64N/D116N
(NN) late reverse transcription (LRT) products in control and MxB-expressing cells. WT and NN curves are black and red, respectively. Dashed lines, values
from MxB-expressing cells. Lower panel, integration as assessed by Alu-R qPCR. (C) Levels of 2-LTR circles using conventional qPCR conditions. (D and E)
Levels of 2-LTR circles using Jxn2 and Jxn1 qPCR conditions, respectively. The 4-member graphs to the left are split into two panels on the right in panels
C-E to highlight the responses of WT (black lines) and NN mutant (red lines) viruses to MxB restriction (dashed lines). Results are an average of
2 independent experiments, with error bars denoting standard deviation (downward bars omitted to ease interpretation of coincident time points).
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ring within the initial ~12 kb of gene regions (Figure 6A
and Additional file 3: Figure S3A-C). The breakdown of
CpG island targeting highlighted that HIV-1 avoids
regions ~1.25 kb upstream of this annotation (Figure 6B
and Additional file 3: Figure S3D). Symmetric peaks of
integration preferences surrounding this “cold spot” were
observed at ~6.25 kb upstream and 3.75 kb downstream
from CpG islands. Although MxB expression did not
grossly affect the overall pattern of CpG island sensing by
the integration machinery, significant differences from
control cells were observed from ~16.25 kb upstream to
15.0 kb downstream from CpG islands (Figure 6B and
Additional file 3: Figure S3E and F).
As expected [41,46], HIV-1 additionally favored inte-
gration into chromosomal regions that were relatively
enriched in genes: as compared to the calculated MRC
value of 8.8 genes per Mb, the virus selected regions that
on average harbored 19.3 genes per Mb of DNA in control
cells. MxB expression significantly altered this preference,
Figure 5 PIC activity and integration site sequencing strategy. (A) PICs extracted from the cytoplasm (left panel) or nucleus (center panel) of
mock-transduced (dark grey bars) or MxB-expressing cells (light grey bars) were assessed for in vitro integration activity. Percent infectivity, determined
48 h after infection (right panel), revealed the level of MxB restriction under these infection conditions. Results are the average of 4 independent
experiments, with error bars denoting standard error of the mean. (B) Integration site sequencing strategy. In the representative HIV-1 provirus
the viral DNA internal to the LTRs is a single bold line and the abutting cellular DNA is two thin lines (the region to be sequenced is in red).
Thin blue lines, asymmetric DNA linker. The bold extensions of PCR primers denote elements required for Illumina sequencing. HIV-1 DNA
harbors numerous MseI sites; only the relevant site downstream from the upstream U5 sequence is shown.
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(Table 1). Similar intermediate effects were previously
noted when cell factors implicated in PIC nuclear import,
for example transportin 3 or RANBP2, were depleted
by RNA interference [45]. To gain insight into the con-
sequences of MxB expression versus transportin 3 or
RANBP2 depletion, percent integration sites were plot-
ted against gene density. MxB expression yielded shifts
in the gene density profile that overall appeared similar
to the shifts elicited by nuclear transport factor depletion
(Figure 6C and D).
MxB GTPase active site residues
We next focused on the characteristics of MxB required
to restrict HIV-1 infection. We tested a moderate panel
of 21 MxB deletion and missense mutant proteins,
which exhibited a range of expression levels and HIV-1
restricting activity (summarized in Additional file 4:
Table 1 Effects of MxB restriction on HIV-1 integration site preferences
a
Library Unique sites Within Refseq
genes (%)
Within 5 kb
(+/− 2.5 kb) of TSS (%)
Within 5 kb (+/− 2.5 kb)
of CpG island (%)
Average gene density within 1 Mb
(+/− 0.5 Mb) of integration sites
b
HOS cells 476 305 302 900 (63.6)
c 14 814 (3.11)
d 13 737 (2.88)
e 19.3
HOS-MxB cells 50 065 29 041 (58.0)
f 1 126 (2.25)
g 986 (1.97)
h 14.0
MRC 476 280 171 999 (36.1) 15 334 (3.22) 13 101 (2.75) 8.8
aStatistical comparisons performed by Fisher’s exact test.
bBased on complete genes. See Figure 6C for statistical analysis.
cP value versus MRC, <2.2 × 10
−308; versus HOS-MxB cells, 4.4 × 10
−132.
dP value versus MRC, 0.002; versus HOS-MxB cells, 2.6 × 10
−35.
eP value versus MRC, 8.4 × 10
−5; versus HOS-MxB cells, 3.5 × 10
−35.
fP value versus MRC, <2.2× 10
−308.
gP value versus MRC, 2.6 × 10
−35.
hP value versus MRC, 7.4 × 10
−27.
Figure 6 Integration patterns in control versus MxB-expressing cells. (A) Number of integration sites counted in 1.25 kb bins (x-axis ticks)
were plotted as percent of total from 30 kb upstream (negative x-axis value) to 30 kb downstream of TSSs. Blue and red lines, data from control and
MxB-expressing HOS cells, respectively; The green plot, MRC values. The sites ~4 kb to 12 kb upstream of TSSs with significantly greater levels of
integration than random in WT HOS cells in the vast majority of cases also mapped within RefSeq genes, which was attributed to the presence of
internal promoters in the human genome [44]. (B) Frequency of HIV-1 integration sites surrounding CpG islands. Line colorings are same as in panel
A. See Additional file 3: Figure S3 for statistical analysis of panel A and B results. (C) Percent integration sites (y-axis) plotted against number of genes
per Mb (x-axis) for infections conducted using control (blue line) and MxB-expressing (red line) HOS cells. Wilcox Rank-Sum test analysis of gene density
targeting values (Table 1) yielded P values < 2.2×10
−302 for all comparisons (WT versus MRC, MxB versus MRC, and WT versus MxB). Fisher’se x a c t
test was therefore conducted on the subset of integration sites that fell between 8 and 19 genes per Mb (bracket). Herein, WT and MxB-expressing
cells harbored 34.8% and 35.4% of all integrations, respectively; the MRC value was 30.2%. The WT versus MRC comparison yielded P <2.2×10
−308.
MxB-expressing cells versus MRC yielded P= 2.8×10
−124 whereas P =0.01 was determined for control versus MxB-expressing cells. (D) Same as in panel
C, except the following data from Ocwieja et al. [45] was analyzed: control siGL2, 7,140 integration sites; TNPO3 si4, 3,923 sites; RANBP2 si6, 2,114 sites.
TNPO3, transportin 3. The panel D graph was smoothed using kernal estimation [45] due to relatively fewer numbers of integration sites.
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targeted the MxB GTPase domain. The GTPase domain
of MxB is highly related to other proteins derived from
t h ed y n a m i nf a m i l yo fl a r g eG T P a s e s ,s u c ha sM x Aa n d
dynamin itself. We found that dynamin side chains
involved in GTP binding were conserved in MxB,
suggesting functional importance (Figure 7A). Mutant
forms of MxB harboring alanine residues at these posi-
tions were stably expressed in HOS cells (Figure 7B and
C). With the exception of K131A, which was expressed at
the lowest level among all tested mutants (Figure 7B and
Additional file 4: Figure S4), the active site mutant MxB
proteins restricted HIV-1 to levels indistinguishable from
that of the WT protein (Figure 7B, dark gray bars).
Though all GTPase mutants exhibited localization similar
to WT MxB by immunofluorescence (Figure 7C), we infer
that the dramatically reduced steady-state expression level
of the K131A protein likely influenced its weakened
restriction activity against HIV-1.
The MxB loops
Human MxA and MxB are highly related proteins
(~56% amino acid identity; ~70% amino acid similarity).
Two areas that exhibit the greatest extent of dissimilarity
between the two proteins are the N-terminal regions
that precede the first helix of the BSE (lengths of ~42
and ~90 residues in MxA and MxB, respectively) and
L o o p 4o ft h es t a l kd o m a i n( l e n g t h so f~ 3 8a n d~ 4 0r e s i d u e s
in MxA and MxB, respectively) (Figure 8A). Because Loop4
is an important specificity determinant of MxA inhibition
of orthomyxoviruses [47], we assessed the importance of
MxB Loop4 in restricting HIV-1 by replacing the 32 amino
acids that span residues 584–615 with a short flexible
stretch of unrelated sequence (GAGAG). Despite the
relative large disruption of endogenous peptide sequence,
this construct retained fairly robust activity, inhibiting
HIV-1 infection by ~5-fold (Figure 8B). Loop4 was not
resolved within the crystal structures of MxA [13,48], but
appears to influence MxA multimerization by making
contacts with adjacent subunits within a multimer [48]. In
fact, though many of the loops present in the stalk of
dynamin superfamily proteins are involved in functional
oligomerization, none of these regions was absolutely
required for MxB antiviral activity. Stalk Loop2 is
required for MxA oligomerization [13], but its removal
only modestly reduced the restriction activity of the
Figure 7 A c t i v i t i e so fM x BG T P a s ea c t i v es i t em u t a n tp r o t e i n s .( A )X-ray crystal structure of dynamin active site with bound phosphomethylphosphonic
acid guanylate ester (GCP) (pdb code 3zyc). Dynamin side chain contacts with GCP (cyan backbone) are labeled, with the corresponding
conserved MxB residue labeled in parenthesis. Dotted black lines denote hydrogen bonds. Remaining colors: red, oxygen atoms; blue, nitrogen;
orange, phosphorus. (B) (top) WT or MxB mutant protein activities against HIV-1 (dark grey), EIAV (light grey) or FIV infection (striped). Results
are an average of at least 6 independent experiments, with error bars denoting 95% confidence intervals. (bottom) Representative western blots
from at least 3 independent experiments. (C) Immunofluorescent microscopy of HOS cells expressing WT MxB or the indicated mutant protein.
Each bar represents a distance of 10 μm.
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P <0.0001). Deletion of Loop1 similarly reduced MxB
antiviral activity by only ~2-fold. MxB mutant G439D
corresponds to yeast Dnm1 assembly mutant G385D
[49], yet the G439D change did not noticeably effect
MxB antiviral activity. Lastly, the R408D mutation in
MxA reduced oligomerization and antiviral activity in an
Influenza A minireplicon system [48]. The corresponding
MxB residue (Arg455) appeared to effect HIV-1 restriction
as well: whereas the R455A mutation only modestly re-
duced antiviral activity, the R455D change largely rendered
MxB unable to inhibit HIV-1 (P <0.0001) (Figure 8B).
Though the steady state level of R455D mutant MxB
expression was less than the WT, it was expressed at
similar levels as GTPase domain mutants S132A and
T151A, which were both fully active (Additional file 4:
Figure S4). The Loop4, Loop2, and Arg455 mutant proteins
notably exhibited more diffuse intracellular staining than
WT MxB, which we infer is due to altered oligomerization
equilibria within the cell. Interestingly, the localization
of the least active mutant, R455D, was most prominently
perturbed, with visible localization within the nucleoplasm
(Figure 8C).
The MxB N-terminal region
The N-terminal 25 residues of MxB harbor a NLS that is
necessary for MxB association with the nucleus [18]. It
was previously noted that an N-terminal truncation mu-
tant lacking these residues (Δ1-25) was inactive against
HIV-1 [11]. We extended this analysis by testing two heter-
ologous N-terminal localization mutants: we appended
the basic NLS PKKKRKV from the SV40 large T anti-
gen onto Δ1-25 (Δ1-25 +NLS) or added the nuclear
export sequence (NES) derived from cAMP-dependent
protein kinase inhibitor alpha onto the full-length protein
(Figure 9A). The mutant proteins expressed similarly
to WT MxB, except for MxB +NES, which was ex-
pressed ~2-fold less than the WT protein (Figure 9B and
Additional file 4: Figure S4). Notably, the level of expres-
sion of MxB +NES was equal to or greater than those
of highly active mutants T151A and S132A (Additional
file 4: Figure S4). As previously observed, deletion of
the initial 25 residues containing the endogenous NLS
rendered MxB inactive against HIV-1 (Figure 9C). Ap-
pending the SV40 NLS onto this truncation protein
however fully restored restriction. Furthermore, the
NES-containing MxB protein was inactive (~1.7-fold
reduction to HIV-1 infection, which did not differ sig-
nificantly from EIAV and FIV controls). These results
show that MxB localization, rather than the specific
sequence of the N-terminal 25 residues, dictates MxB
activity against HIV-1 infection. Obvious WT-like nuclear
rim staining was not observed with either the Δ1-25 or
Δ1-25+NLS mutants (Figure 9D), though prominent
Figure 8 MxB stalk mutants and antiviral activity. (A) The MxB protein schematic highlights regions of sequence diversity from the human
MxA protein; each red dot denotes an MxB position where 5 consecutive residues differed from MxA. (B) Antiviral activities of MxB stalk mutant
proteins. Results are an average of at least 5 independent experiments, with error bars denoting 95% confidence intervals. (C) Representative
immunofluorescent microscopy results; white bar, 10 μm. See Additional file 4: Figure S4 for results of quantitative western blotting.
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assessment.
We next assessed the importance of the remaining
sequence found within the unique N-terminal region of
MxB. We first deleted these residues (26–90) from both ac-
tive forms, i.e., from the full-length protein and from the
Δ1-25+ NLS variant (Figure 10A). Both truncated forms
were expressed similarly to the WT protein (Figure 10B and
Additional file 4: Figure S4). Residues 26–90 of MxB were
absolutely required for antiviral activity in both contexts
(Figure 10C). Notably, Δ1-90+NLS exhibited dramatically
altered localization: the protein localized predominantly
within the nucleus, with distinct nucleolar staining
(Figure 10D, upper row). Lastly, we engineered a series of
20–25 amino acid deletions within residues 26–90 to nar-
row down specific regions of functional importance, again
in the context of our two active WT and Δ1-25+NLS
forms (Figure 10A). Deletion of residues 27–50 abolished
Δ1-25+ NLS antiviral activity and significantly crippled the
activity of the construct with an intact N-terminus
(~2.2-fold residual restriction activity). Deletions of
amino acids 51–70 and 71–90 were far less disruptive,
as the corresponding MxB proteins exhibited >4.5-fold
restrictive activity in the context of the WT N-
terminus. The deletion of these regions in the context
of the Δ1 - 2 5 + N L Sv a r i a n ts u g g e s t e dt h e ym i g h ts t i l l
contribute to MxB activity, as these two proteins were
largely attenuated for antiviral function (Figure 10C).
Discussion
MxB was recently discovered to inhibit HIV-1, yet little
consensus was found on the stage(s) of infection that was
primarily affected. The results reported here shed light on
the targeted steps of the viral lifecycle as well as aspects of
MxB function that are required for HIV-1 restriction.
CA is a major determinant of HIV-1 restriction by MxB
Our work confirms that viral CA is a major genetic deter-
minant of MxB restriction. Many individual CA missense
mutations, including those of residues on distantly located
surfaces of the CA N-terminal domain, rendered the virus
resistant to MxB restriction (Figure 2). Similarly, a large
set of CA mutations in the N- and C-terminal domains of
CA were recently found to confer resistance to MxB [50].
Figure 9 Functional heterologous NLS and NES sequences. (A) Schematic of MxB nuclear localization mutants. The location of heterologous
NLS and NES sequences are denoted in blue and red, respectively; the common C-terminal HA tag is in green. Western blotting (B), antiviral activity
(C), and immunofluorescent microscopy (D) of WT MxB and mutant proteins. Results in panel C represent the geometric mean of at least 8 independent
experiments, with error bars denoting 95% confidence intervals. The differences in HIV-1 restriction by MxB Δ1-25 or MxB + NES with WT MxB was highly
significant (P <0.0001). The horizontal bars in panel D represent the distance of 10 μm.
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with those observed previously for other CA targeting
host proteins, such as TRIM5α, CPSF6358, and NUP153
(Figure 2E,F and Additional file 1: Figure S1). Although
more work would be required to determine why MxB
activity did not correlate as strongly with restriction by
the artificial Trim-CPSF6358 fusion protein, the pattern
of Trim-CPSF6358 restriction appears generally distinct
from those imparted by other factors such as TRIM5α,
Trim-NUP153C, and the parental non-fused CPSF6358
protein [26]. Perhaps the higher-order multimerization
that is instilled through the TRIM RING, B-box, and
coiled-coil domains [51,52] helps to counteract the
brunt of viral changes that otherwise confers resistance
to CPSF6358.
Our results suggest that a relatively common pleio-
tropic factor, such as differential CA core uncoating,
may simultaneously perturb viral sensitivity to a range of
CA-targeting host proteins, including MxB. While this
work was in review, Fricke et al. [53] reported that MxB
Figure 10 Activity and localization of N-terminal deletion mutants. Schematic (A), western blotting (B), antiviral activity (C), and
immunofluorescence microscopy (D) of N-terminal deletion mutants. Panel C results represent the geometric mean of at least 6 independent
experiments, with error bars denoting 95% confidence intervals. All mutant proteins restricted HIV-1 infection to significantly lower levels than
WT MxB (P <0.002). The bars in panel D represent 10 μm.
Matreyek et al. Retrovirology 2014, 11:90 Page 14 of 20
http://www.retrovirology.com/content/11/1/90expression increased the level of pelletable CA during
acute HIV-1 infection, indicating that the restriction factor
alters uncoating through stabilization of incoming viral
capsids. The effect caused by CA mutations may be related
to MxB-CA binding, as we have observed that MxB-HA in
cell extracts can co-sediment in vitro with multimerized
HIV-1 CA structures [54]. Fricke et al. [53] reported similar
co-pelleting between ectopically expressed MxB protein
and recombinant CA assemblies in vitro.
MxB determinants required for HIV-1 restriction
Aided by the relatively high sequence conservation be-
tween MxA and MxB, we compared genetic determinants
of MxB restriction with those previously determined to be
required for MxA antiviral activity. Our expanded panel
of putative active site mutants supported the dispensability
of MxB GTPase activity for HIV-1 inhibition [9,11]. This
contrasts with MxA inhibition of Influenza virus, which
requires GTP hydrolysis [9]. Concordantly, we found that
the various loops extending from the MxB stalk were not
critical for antiviral activity. This includes Loop4, which is
one of two locations in MxB that exhibits the greatest
sequence dissimilarity with MxA. Notably this finding
contrasts with the importance of MxA Loop4 for inhib-
ition of Influenza A and Thogotovirus infection [47]. The
equilibrium of intracellular MxB multimerization or
aggregation likely has an effect on its antiviral activity:
the MxB stalk mutants with diffuse localization were
less active than the WT protein, with the R455D mutant
that exhibited prominent intranuclear staining nearly
inactive against HIV-1 (Figure 8). The interpretation of
R455D loss-of-function is therefore cautioned by the fact
that this mutant may largely be in the wrong place in the
cell to exert any potential antiviral activity. Although we
have not directly measured MxB protein multimerization,
the participation of peptide loops and specific residues
(Gly439, Arg455) is inferred from the analogous role of
these conserved features in the oligomerization of other
dynamin family members [13,48,49].
The other part of MxB with greatest dissimilarity to
MxA is the N-terminal region that precedes the first
helix of the common BSE. The importance of the first
25 amino acids for antiviral activity was indeed due to
its NLS, as the heterologous SV40 NLS conferred full
restriction activity to the otherwise dead Δ1-25 construct
(Figure 9). Additionally, forced mislocalization of MxB by
appending an exogenous NES disrupted antiviral activity,
further demonstrating the importance of MxB subcellular
localization. In contrast to the first 25 residues, the
remaining ~65 residues of the N-terminal stretch contrib-
uted to antiviral activity, yet could not be complemented
by addition of a heterologous NLS. Thus, particular func-
tions conferred by the peptide sequences in this sub-region
appear important. The constructs generally exhibited less
antiviral activity when expressed in the context of the Δ1-
25+ NLS variant, suggesting a potential interplay between
regions within the N-terminal 90 residues of the protein.
The sequence present in residues 26–50 were particularly
important for MxB activity; this finding is consistent with
recent results by Busnadiego et al., who demonstrated indi-
vidual residues within this region, specially amino acids
37–44, to determine antiviral specificities between MxB
proteins isolated from different animal species [50]. Also
consistent with our findings is the result that the transfer
of MxB residues 1–91 can confer potent anti-HIV-1 activ-
ity to human MxA [55]. Although Fricke et al. have
highlighted the importance of the N-terminal 25 residues
in CA binding [53], additional work is required to more
fully characterize the precise role of the unique N-terminal
region of MxB for its antiviral mechanism.
MxB restricts PIC nuclear import and HIV-1 integration
Similar to the results of Kane et al. [11], we found that
MxB expression decreased the amount of 2-LTR circles
to a level that was intermediate to the decreases observed
for HIV-1 integration and virus infection (Figure 4). Con-
cordantly, the extent at which MxB restricted the D64N/
D116N IN mutant, a virus whose low level of expression
is independent of functional integration, paralleled the 2-
LTR circle defect. These observations indicated that a step
in the HIV-1 life cycle after nuclear entry was additionally
affected by MxB expression. Interestingly, PICs isolated
from both the cytoplasm and nucleus of MxB-expressing
cells were fully active (Figure 5A), suggesting the defect to
integration lies outside the catalytic capacity of the IN en-
zyme. These results indicate that MxB restriction disrupts
multiple nuclear steps to infection, which likely com-
pound to form its potent antiviral activity (Figure 3C,D).
It may at first glance seem counterintuitive that a pro-
tein that accumulates in the cytoplasm and at the nuclear
rim at steady-state [18] (Figure 1C) can potently inhibit
nuclear events. Integration sites from control and MxB-
expressing cells were determined to gain insight into the
post nuclear entry block to HIV-1 infection. Our data
revealed rather dramatic effects of MxB expression on the
distribution of integrated proviruses. Significant differ-
ences in integration within genes and nearby TSSs and
CpG islands were evident (Table 1, Figure 6A, B, and
Additional file 3: Figure S3). The ability for HIV-1 to
integrate into relatively gene-dense regions of chromatin
was additionally affected. Moreover this response seemed
similar to those previously noted by depleting cellular
import factors such as transportin 3, RANBP2 [45]
(Figure 6C,D), or NUP153 [42,56]. These observations
seemingly agree with recent research that indicates that
HIV-1 PIC nuclear import and integration may be func-
tionally linked [42,45,56,57]. For example, CA point
mutations [42,57], in addition to depletion of cellular
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tribution of HIV-1 integration within chromatin. The
tendency for HIV-1 to integrate into host DNA in
the vicinity of the nuclear periphery is moreover con-
sistent with these observations [58]. We accordingly
speculate that additional investigations into the
mechanism(s) of MxB restriction may uncover fur-
ther novel aspects of HIV-1 PIC nuclear import and
integration.
Conclusions
Our results are consistent with the notion that MxB
restricts HIV-1 after DNA synthesis at steps that are
coincident with PIC nuclear import and integration. This
conclusion was based not only on qPCR analysis of DNA
replication intermediates, but also on relative degrees
of HIV-1 CA and IN mutant virus sensitivities to MxB
antiviral function and results of integration site sequencing.
On the host factor side, our results confirm prior reports
that GTPase active site residues are largely dispensable
for restriction [9,11] and importantly extend these
observations to show that various stalk domain loops,
which mediate the functional oligomerization of related
enzymes, are in large part dispensable for restriction of
H I V - 1i n f e c t i o n .W ea d d i t i o n a l l yc o n f i r m e dt h ei m p o r t -
ance for the N-terminal 25 residues of MxB [11] and
extended this finding to show that the heterologous
basic-type NLS from SV40 large T antigen fully rescued the
restriction activity of the Δ1-25 variant. Approximate
quarter-size deletions of the N-terminal 90 residues add-
itionally highlighted an important function within residues
27–50 that is independent of the endogenous NLS within
the N-terminal 25 residues of MxB or the added, heterol-
ogous SV40 NLS. We therefore conclude that the
N-terminal 90 residues of MxB likely contains critical
bipartite functional elements for HIV-1 restriction activity.
Methods
Cells
HEK293T and HOS cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 0.1 mg/ml streptomycin. HOS cells stably
transduced by LPCX-based vectors were selected and
maintained with 2 μg/ml puromycin.
Plasmids
Plasmids encoding green fluorescent protein (GFP) reporter
HIV-1, SIVmac251, EIAV, FIV, and MLV viral vectors have
been described previously [25]. HIV-1 CA, IN, NC, and RT
mutations were generated with site-directed mutagenesis of
the HIV-1NL43-based pHP-dI-N/A packaging plasmid [59]
(AIDS Research and Reference Reagent Program [ARRRP]).
WTand mutant plasmids were cotransfected with the pHI-
Luc transfer vector [25]. Plasmid pLPCX was obtained
from Clontech.
DNA sequence encoding human MxB (accession number
NM_002463.1) was engineered with a C-terminal HA-tag
into the pLPCX-based MLV transduction vector. Mutations
were generated using site-directed mutagenesis. The
ΔLoop4 mutation was generated by replacing nucleotides
corresponding to MxB residues 584 to 615 with those
encoding the GAGAG peptide. Stalk Loop1 (residues
440 to 448) and Loop2 (residues 488–497) were replaced
with the sequence GSGGSG. The Δ25 mutation was
generated by deleting sequences encoding Met1 to
Glu25. The NLS Δ25 mutant was created by inserting
the SV40 large T antigen NLS sequence (PKKKRKV)
subsequent to the initial Met but preceding Asn27. The
NES mutant was generated by adding the NES-derived
sequence from cAMP-dependent protein kinase inhibitor
alpha (LALKLAGLDI) subsequent to the initial Met but
preceding Ser2.
Infection assays and qPCR
MxB-expressing or parental HOS cells (10
4) seeded onto
wells of 48-well plates were infected in duplicate with
GFP reporter viruses. Percentages of GFP-positive cells
were determined 48 h post infection using a FACSCanto
flow cytometer. MxB-expressing or parental HOS cells
(2,500) seeded onto wells of 96-well plates were infected
in triplicate with luciferase reporter viruses, which were
lysed and analyzed 48 h post infection. For qPCR assays,
MxB-expressing or parental HOS cells (2 ×10
6) were
infected with 2.5×10
7 RT counts per minute (RTcpm) of
HIV-1 luciferase reporter virus in a 10 cm dish in the
presence or absence of 20 μM efavirenz (EFV; obtained
from ARRRP) to define residual plasmid DNA levels
potentially carried over from transfection. After 2 h,
cells were washed with phosphate buffered saline (PBS),
harvested for the initial time point, and replated into
6 cm plates in the presence or absence of EFV. Cells
were collected at additional time points, and DNA was
extracted with a QIAamp DNA Mini kit (Qiagen).
QPCR for the accumulation of viral late reverse tran-
scription (LRT) products and 2-LTR-containing circles
were performed as previously described [25]. The quanti-
tation of intact 2-LTR circle junctions was performed
using primers AE4450 and AE4451 combined with
Taqman probe AE2623 (Jxn1; FAM-AAAATCTCTAG
CAGTACTGGAAGGGCTAAT-TAMRA), or primers
AE4450 and AE5209 (GTGAATTAGCCCTTCCAG
TAC) with Taqman probe AE4452 (Jxn2). Values from
EFV-treated samples were subtracted from nondrug-
treated values. Integration was assessed using nested
qPCR as previously described [25].
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Control and MxB-expressing HOS cells (5×10
6) infected
with GFP reporter virus for 6 h were washed and then
incubated for 5 d to enable dissolution of unintegrated
viral DNA prior to DNA isolation using the DNeasy Blood
and Tissue Kit (Qiagen). DNA (20 μg) digested overnight
with MseI and BglII was purified using the QIAquick PCR
Purification Kit (Qiagen). A double-stranded asymmetric
linker was made by heating 10 μM oligonucleotide
AE5972 (5′-TAGTCCCTTAAGCGGAG/3AmMO/-3′)
with 10 μMA E 5 9 7 4( 5 ′-GTAATACGACTCACTATA
GGGCNNNNNCTCCGCTTAAGGGAC-3′) for 2 min
at 90°C in 10 mM Tris–HCl, pH 8.0–0.1 mM EDTA,
followed by slow cooling to room temperature. The
random nucleotides at the center of AE5974 comprise a
“serial number”, which was not applicable to this study.
Linker DNA (1.5 μM) was ligated with digested cellular
DNA (1 μg) overnight at 16°C in four parallel reactions,
and the DNAs were pooled and re-purified using the
QIAquick PCR Purification Kit. PCRs multiplexed into
eight separate samples each contained 1 μgD N As u b -
strate and primers AE5976 and AE5971 in Advantage
2 PCR Buffer. AE5976 (5′-CAAGCAGAAGACGGCA
TACGAGATCGGTCTCGGCATTCCTGCTGAACCGC
TCTTCCGATCTGTAATACGACTCACTATAGGGC-
3′), which was complementary to the linker, additionally
contained the Illumina P7 adapter sequence (bold charac-
ters) and sequence complementary to the Illumina Paired
End read 2 sequencing primer (italics). AE5971 (5′-AAT
GATACGGCGACCACCGAGATCTACACTCTTTCCC
TACACGACGCTCTTCCGATCTCTAGTGAGATCCCT
CAGACCCTTTTAGTCAG-3′), which contained HIV-1
U5 sequences, also contained the Illumina P5 adapter
sequence (bold characters) and a barcode (italics) that
was varied among similar primers to track the different
samples. The sequence between P5 and the barcode is
complementary to the Illumina Read 1 sequencing primer.
PCRs were incubated at 94°C for 4 min, followed by six
cycles at 94°C for 15 sec, 60°C for 30 sec, and 68°C for
45 sec. Reactions were subsequently cycled 24 times at
94°C for 15 sec, 55°C for 30 sec, and 68°C for 45 sec,
which was followed by a final extension for 10 min at
68°C. Pooled PCRs were purified using the QIAquick
PCR Purification Kit and sequenced on the Illumina
MiSeq platform at the Dana-Farber Cancer Institute
Molecular Biology Core Facilities and on the Illumina
HiSeq platform at the University of California at Irvine
Genomics High Throughput Facility.
Bioinformatics analysis of integration sites
Representative transcripts from sets of transcripts with
identical coordinates yielded 26,251 unique RefSeq human
genes from the UCSC Genome Bioinformatics browser
[60]; 18,273 genes that yielded overlapping coordinates
were omitted from the analyses. The MRC was generated
following in silico digestion of the hg19 reference genome
with MseI and BglII. CpG island coordinates were down-
loaded from the UCSC Genome Bioinformatics browser.
LTR sequences were trimmed from each read; dupli-
cates were removed from trimmed reads and the resulting
sequences were aligned to hg19 by Blat [61]. Alignments
with e values less than 0.05 and that matched starting
from the first nucleotide after the LTR were selected.
Matches to multiple genomic sequences were removed on
the basis of bit scores (differences <0.0001) to identify
unique alignments. The start position of the alignment
on the positive strand was chosen as the insertion site
whereas 4 nucleotides were subtracted from the start
position of alignments on the negative strand.
To map insertions relative to TSSs, the distances between
insertions and the nearest TSS were calculated and these
were summed in 1.25 kb bins. If insertions were upstream
of the nearest TSS the distances were plotted with negative
numbers. To map insertions relative to CpG islands the
inserts were given negative distances if the coordinates of
an insertion were less than the coordinates of the nearest
CpG. Positive distances were used if the insertions had lar-
ger coordinates than that of the nearest CpG. Bedtools was
used to calculate the gene densities for each insertion [62].
Immunofluorescence microscopy
Parental HOS cells or cells stably expressing HA-epitope
tagged MxB proteins were cultured on Nunc Lab-Tek II
chamber slides (Thermo Scientific). Cells were fixed with
4% paraformaldehyde for 10 min, washed with PBS, and
permeabilized with ice-cold MeOH for 10 min. The cells
were then blocked with blocking buffer (PBS containing
10% FBS) for 30 min, and stained with 1:300 dilution of
anti-HA antibody 16b12 (Covance). After a 30 min wash
with blocking buffer, the cells were incubated for 1 h
with a 1:1,000 dilution of an Alexa Fluor 555 conjugated
goat anti-mouse IgG antibody (Invitrogen) as well as
Hoescht 33342 (Invitrogen) at 1 μg/ml. After an additional
30 min wash with PBS, the samples were covered with
mounting medium [150 mM NaCl, 25 mM Tris–HCl
pH 8.0, 0.5% N-propyl gallate, and 90% glycerol]. The
processed samples were analyzed on a Nikon Eclipse spin-
ning disk confocal microscope at the Dana-Farber Cancer
Institute Confocal and Light Microscopy core.
Western blotting
Cells pelleted at 300× g were resuspended in PBS sup-
plemented with 0.2% NP-40 and 10 U/ml Turbo DNAse
(Ambion) and incubated for 30 min on ice. Samples were
mixed with protein sample loading buffer to the final
concentrations of 62.5 mM Tris–HCl, pH 6.8, 2% sodium
dodecyl sulfate, 10% glycerol, 5% 2-mercaptoethanol, and
0.001% bromophenol blue. The samples were heated for
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gels, and transferred to polyvinylidene fluoride membranes.
MxB-HA was detected with a 1:2000 dilution of HRP-
conjugated 3F10 antibody (Roche), or a 1:1000 dilution of
anti-MxB antibody N-17 sc-47197 (Santa Cruz Biotechnol-
ogy). Beta-actin was detected with a 1:10,000 dilution of
HRP-conjugated antibody clone AC-15 (Sigma). Western
blots were developed using ECL prime reagent (GE Health-
care Life Sciences) and imaged with a ChemiDoc MP
imager (Bio-Rad) equipped with Image Lab 4.1 software.
The amount of MxB-HA or beta-actin signal in each
sample was quantitated relative to the level of each signal
compared to a matched WT MxB-expressing sample. The
MxB expression ratio was calculated by dividing the
MxB-HA signal with that of beta-actin, with the level
for WT MxB expression set to 1.
In vitro integration assay
The in vitro integration activity of PICs isolated from
acutely infected cells was determined essentially as pre-
viously described [63,64]. In brief, MxB-expressing and
control HOS cells (2.1 ×10
7) plated into three 15 cm
dishes were infected the next day with 15 ml of fresh
GFP reporter HIV-1 per plate in the presence of 8 μg/ml
polybrene for 7 h, at which time cells were harvested for
biochemical fractionation. Multiplicity of infection (MOI)
was determined two days later by flow cytometry, with an
average MOI on MxB-expressing cells of ~0.2 across
experiments. PICs isolated from cytoplasmic and nuclear
extracts were reacted with plasmid target DNA in vitro,
and the extent of viral DNA integration was quantified
using nested PCR. The first round (27 cycles) amplified
covalently linked HIV-plasmid sequences; 1 μlo f1 0 0 - f o l d
diluted first round PCR product was used in the HIV-
1-specific second round qPCR. Values obtained from
parallel PCRs that omitted the plasmid-specific primers
from the first round of amplification were subtracted from
matched experimental samples. Levels of IN-mediated
DNA strand transfer activities were normalized to the
total level of HIV-1 DNA (qPCR for late reverse tran-
scription products) in each extract.
Statistical analysis
Correlations between variablesw e r ea s s e s s e db yS p e a r m a n
rank correlation, and significances of pair-wise differences
were calculated by two-tailed Student’s t-test, using Prism6
software (Graphpad). Statistical differences between inte-
gration site datasets were calculated using R [65].
Additional files
Additional file 1: Figure S1. Scatterplot comparisons of MxB sensitivity
with the indicated CA-mediated host cell determinant. Results of at least
6 independent experiments are expressed as log10 averages.
Additional file 2: Figure S2. Relative resistance of IN mutant D64N/
D116N to MxB restriction over a range of virus inoculum. (A) Levels of WT
(two darker shades of grey) and D64N/D116N (NN) IN mutant (lighter
shades of grey) infectivity, which were normalized to the WT based on
input levels of exogenous RT activity, in control HOS versus MxB-expressing
cells. The level of WT infectivity in control cells at the highest multiplicity of
infection, which was 25 RT cpm per cell, was set to 100%. (B) Re-plot of
panel A to highlight extent of WT (dark grey) versus IN mutant NN (light
grey) restriction by MxB at the different multiplicities of infection. The results
are the averages of two independent experiments, with error bars denoting
standard deviation.
Additional file 3: Figure S3. Statistical analysis of HIV-1 integration
frequencies surrounding TSSs and CpG islands. (A) P value calculations
(Fisher’s exact test) for Figure 6A data graphed as three separate curves
(control HOS cells versus MRC, blue; MxB-expressing cells versus MRC,
green; control versus MxB-expressing cells, red). The purple horizontal line
indicates the statistical cutoff value (1.3= −log10(0.05)). The thumbs down
sign indicates regions where integration in control HOS cells was significantly
disfavored as compared to the corresponding MRC value (relevant bins
marked by red cross). The flattening of the WT curve from 2.5 kb to 16.25 kb
downstream of TSSs reflects P values <2.2×10
−308.( Ba n dC )E x p a n d e dv i e w s
of MxB versus MRC (panel B) and WT versus MxB (panel C) curves from panel
A. (D) P value analysis of CpG island targeting data from Figure 6B. Other
labeling is same as in panel A of this figure. (E and F) Expanded views of
panel D green (MxB versus MRC) and red (WT versus MxB) curves.
Additional file 4: Figure S4. Scatterplot comparison of WT and mutant
MxB-HA expression level with HIV-1 restriction activity. Quantitated levels
of mutant MxB-HA expression are expressed relative to WT MxB, which
was set to one (vertical dotted line). Blue, single missense mutants;
brown, NES and deletion mutant constructs. Expression results are the
mean of at least 3 independent experiments, with error bars denoting
standard error.
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